{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mesothelial+Neoplasm&page=2", "query": { "condition": "Mesothelial Neoplasm", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mesothelial+Neoplasm&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T20:32:21.751Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00002465", "title": "High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Endometrial Cancer", "Malignant Mesothelioma" ], "interventions": [ { "name": "megestrol acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Vincent Medical Center - Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "1987-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-11-06", "last_synced_at": "2026-06-25T20:32:21.751Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002465" }, { "nct_id": "NCT02859415", "title": "Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Neoplasms", "Lung Neoplasms", "Mesothelioma", "Thymus Neoplasms", "Neoplasms, Germ Cell and Embryonal" ], "interventions": [ { "name": "Mithramycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2019-08-08", "completion_date": "2021-12-01", "has_results": true, "last_update_posted_date": "2022-04-05", "last_synced_at": "2026-06-25T20:32:21.751Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02859415" }, { "nct_id": "NCT01843374", "title": "Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Unresectable Pleural or Peritoneal Malignant Mesothelioma" ], "interventions": [ { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 571, "start_date": "2013-05-17", "completion_date": "2026-06-30", "has_results": true, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-06-25T20:32:21.751Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 17 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01843374" }, { "nct_id": "NCT01552434", "title": "Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Neoplasm", "Castleman Disease", "Digestive System Carcinoma", "Erdheim-Chester Disease", "Lip and Oral Cavity Carcinoma", "Lymphangioleiomyomatosis", "Malignant Endocrine Neoplasm", "Malignant Female Reproductive System Neoplasm", "Malignant Male Reproductive System Neoplasm", "Malignant Neoplasm", "Malignant Respiratory Tract Neoplasm", "Malignant Thoracic Neoplasm", "Malignant Urinary System Neoplasm", "Mesothelial Neoplasm", "Metastatic Malignant Neoplasm", "Metastatic Urothelial Carcinoma", "Neurofibromatosis Type 2", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Breast Carcinoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Digestive System Carcinoma", "Recurrent Female Reproductive System Carcinoma", "Recurrent Male Reproductive System Carcinoma", "Recurrent Malignant Neoplasm", "Recurrent Pharyngeal Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Malignant Neoplasm", "Soft Tissue Neoplasm", "Stage III Breast Cancer AJCC v7", "Stage III Pharyngeal Cancer", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Pharyngeal Cancer", "Stage IVA Pharyngeal Cancer", "Stage IVB Pharyngeal Cancer", "Stage IVC Pharyngeal Cancer", "Thyroid Gland Neoplasm" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 154, "start_date": "2012-10-16", "completion_date": "2026-05-08", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-06-25T20:32:21.751Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01552434" }, { "nct_id": "NCT03975387", "title": "Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "ASTX295", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2019-07-11", "completion_date": "2024-08-15", "has_results": false, "last_update_posted_date": "2025-04-09", "last_synced_at": "2026-06-25T20:32:21.751Z", "location_count": 11, "location_summary": "Duarte, California • Los Angeles, California • Newport Beach, California + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03975387" }, { "nct_id": "NCT06251310", "title": "SW-682 in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Mesothelioma, Malignant" ], "interventions": [ { "name": "SW-682", "type": "DRUG" }, { "name": "Combination Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 186, "start_date": "2024-07-31", "completion_date": "2027-01-18", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-06-25T20:32:21.751Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06251310" }, { "nct_id": "NCT03074513", "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Appendix Adenocarcinoma", "Human Papillomavirus-Related Anal Squamous Cell Carcinoma", "Human Papillomavirus-Related Cervical Squamous Cell Carcinoma", "Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis", "Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma", "Neuroendocrine Carcinoma", "Pancreatic Neuroendocrine Tumor", "Recurrent Merkel Cell Carcinoma", "Recurrent Nasopharynx Carcinoma", "Recurrent Peritoneal Malignant Mesothelioma", "Recurrent Pleural Malignant Mesothelioma", "Stage III Merkel Cell Carcinoma AJCC v7", "Stage III Nasopharyngeal Carcinoma AJCC v7", "Stage III Pleural Malignant Mesothelioma AJCC v7", "Stage IV Merkel Cell Carcinoma AJCC v7", "Stage IV Nasopharyngeal Carcinoma AJCC v7", "Stage IV Pleural Malignant Mesothelioma AJCC v7", "Stage IVA Nasopharyngeal Carcinoma AJCC v7", "Stage IVB Nasopharyngeal Carcinoma AJCC v7", "Stage IVC Nasopharyngeal Carcinoma AJCC v7", "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2017-03-03", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-06-25T20:32:21.751Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03074513" }, { "nct_id": "NCT05238883", "title": "A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastric Cancer", "Renal Cell Carcinoma", "Melanoma", "Sarcoma", "Testicular Germ Cell Tumor", "Cervical Cancer", "Mesothelioma", "Non Small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "HFB200301", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HiFiBiO Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2022-03-10", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-06-25T20:32:21.751Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05238883" }, { "nct_id": "NCT00024271", "title": "Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Mesothelioma" ], "interventions": [ { "name": "recombinant interferon gamma", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "mitomycin C", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "hyperthermia treatment", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Herbert Irving Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-06", "last_synced_at": "2026-06-25T20:32:21.751Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00024271" }, { "nct_id": "NCT04913337", "title": "Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mesothelioma", "Glioblastoma", "Renal Cell Carcinoma", "Non Small Cell Lung Cancer", "Melanoma", "Pancreatic Ductal Adenocarcinoma", "Gastric Cancer", "Squamous Cell Carcinoma of Head and Neck", "Cholangiocarcinoma", "Breast Cancer", "Ovarian Cancer", "Cervical Cancer", "Endocervical Cancer", "Colorectal Cancer", "Esophageal Cancer" ], "interventions": [ { "name": "NGM707", "type": "DRUG" }, { "name": "NGM707 plus pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NGM Biopharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 179, "start_date": "2021-06-09", "completion_date": "2025-07", "has_results": false, "last_update_posted_date": "2024-10-02", "last_synced_at": "2026-06-25T20:32:21.751Z", "location_count": 20, "location_summary": "Los Angeles, California • Newport Beach, California • Santa Monica, California + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04913337" } ] }